Particle.news
Download on the App Store
16 ARTICLES
·
4mo ago

Roche Announces $50 Billion U.S. Investment to Expand Manufacturing and R&D

The Swiss pharmaceutical giant will create over 12,000 jobs and build new facilities across multiple states in response to potential U.S. drug import tariffs.

Roche is attempting to placate Trump in his trade vendetta.
Signage for Roche Holding AG on a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023. Swiss pharma giants Roche and Novartis AG embody opposing approaches to solving a fundamental puzzle: how to placate shareholders and keep growing in an industry where the hunt for the next blockbuster drug is paramount. Photographer: Stefan Wermuth/Bloomberg
BASEL, SWITZERLAND - APRIL 11: A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Before US President Donald Trump postponed a range of imminent tariffs, Switzerland was facing a daunting 31% levy on most Swiss goods to imported to the United States, a higher rate than would have been imposed on European Union countries. Such a tariff would've been high damaging to iconic Swiss industries like chocolate and watchmaking. The reprieve will provide breathing room for Swiss officials looking to negotiate a deal with the US, although Swiss goods will still face a 10% tariff in the meantime, and the fate of a potential separate tariff on pharmaceuticals is unknown. (Photo by Sedat Suna/Getty Images)
Image

Overview

  • Roche will invest $50 billion in the U.S. over the next five years, expanding its footprint in manufacturing and research and development.
  • The investment aims to create more than 12,000 jobs, including 6,500 in construction and 1,000 directly at Roche facilities.
  • New projects include a gene therapy facility in Pennsylvania, a continuous glucose monitoring plant in Indiana, and an AI-focused R&D hub in Massachusetts.
  • A 900,000-square-foot weight-loss drug manufacturing center will also be built, with the location yet to be announced.
  • The move follows President Trump's proposed tariffs on imported pharmaceuticals, with Roche planning to export more medicines from the U.S. than it imports once expansions are complete.